On December 20, 2023, BioMarin Pharmaceutical Inc. announced that it had entered into a cooperation agreement with Elliott Investment Management L.P., Elliott Associates, L.P., and Elliott International, L.P. regarding the composition of the Company?s Board of Directors, the establishment of an ad hoc Strategic and Operating Review Committee of the Board and certain other matters. The Company stated that pursuant to the cooperation agreement, the Company has agreed, among other things, to (i) increase the size of the Board to 15 directors, (ii) appoint Barbara Bodem, Athena Countouriotis, and Mark Enyedy as independent directors with initial terms expiring at the Company?s 2024 annual meeting of stockholders, (iii) appoint Alexander Hardy, Richard Meier, Maykin Ho, Barbara Bodem and Mark Enyedy to the Committee with Richard A. Meier as the Chair of the Committee, and (iv) at an appropriate time following the Board reaching its determinations regarding the Committee?s review, hold an investor day in 2024.